Sandra Parks
Family Medicine · Beatrice, NENPI 1679560700
Payments from drug & device makers
Across 94 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$388
- Cook Medical LLC$209
- Pfizer$154
- Novartis$131
- Novo Nordisk$127
- Amgen$117
- plus $638 from 18 others
What the payments were for
- Food & beverage$1,74799%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $388 |
| Cook Medical LLC | 3 | $209 |
| Pfizer | 10 | $154 |
| Novartis | 8 | $131 |
| Novo Nordisk | 8 | $127 |
| Amgen | 8 | $117 |
| Astellas Pharma US Inc | 3 | $86 |
| Abbott | 4 | $84 |
| Boehringer Ingelheim | 1 | $63 |
| Johnson & Johnson | 3 | $54 |
| AstraZeneca | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Merck | 2 | $33 |
| Lilly USA, LLC | 2 | $27 |
| Boston Scientific | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| GSK | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hemospray$156
How this compares
$1,765 in reported general payments places this provider in the 70th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 104 | $99,798 |
| XareltoRivaroxaban | 77 | $57,047 |
| JardianceEmpagliflozin | 75 | $52,945 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $40,223 |
| FarxigaDapagliflozin Propanediol | 39 | $25,110 |
| EliquisApixaban | 32 | $23,989 |
| MounjaroTirzepatide | 13 | $13,977 |
| Repatha SureclickEvolocumab | 27 | $13,788 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $13,523 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $12,435 |
| JanuviaSitagliptin Phosphate | 18 | $10,065 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,891 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $6,462 |
| LinzessLinaclotide | 12 | $6,197 |
| DiovanValsartan | 11 | $4,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $127 | $99,798104 claims |
| Johnson & JohnsonXarelto | $54 | $57,04777 claims |
| Boehringer IngelheimJardiance | $63 | $52,94575 claims |
| PfizerEliquis, Dilantin | $154 | $27,06545 claims |
| AstraZenecaFarxiga | $46 | $25,11039 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $16 | $22,32632 claims |
| Lilly USA, LLCMounjaro, Insulin Lispro | $27 | $17,37049 claims |
| MerckJanuvia | $33 | $10,06518 claims |
| AbbVieLinzess, Synthroid | $388 | $9,66468 claims |
| NovartisDiovan | $131 | $4,01911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Beatrice
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.